Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.81 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | PSMB1 | P20618 | 7/20 | 0.70 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.70 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | ESR1 | P03372 | 1/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.63 |
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | THRB | P10828 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223800 | 1.00 | KCNH2 (0.81) | KCNH2HRH3KDM4EPSMB1PSMB5 | |
| Hydrochloric Acid SCHEMBL8404070 | 0.99 | KCNH2 (0.80) | KCNH2HRH3KDM4EPSMB1PSMB5 | |
| SCHEMBL21408538 | 0.99 | HRH3 (0.79) | KCNH2HRH3KDM4EPSMB1PSMB5 | |
| SCHEMBL4224568 | 0.93 | HRH3 (0.93) | KCNH2HRH3KDM4EKMT2AALDH1A1 | |
| SCHEMBL4096430 | 0.90 | HRH3 (1.00) | KCNH2HRH3KDM4EALDH1A1LMNA | |
| SCHEMBL17758913 | 0.88 | HRH3 (0.72) | KCNH2HRH3KDM4EPSMB1PSMB5 | |
| SCHEMBL4441360 | 0.87 | SMN1; SMN2 (0.73) | KCNH2HRH3KDM4EPSMB1PSMB5 | |
| SCHEMBL9199244 | 0.87 | KCNH2 (0.63) | KCNH2HRH3KDM4EPSMB1PSMB5 | |
| SCHEMBL5681637 | 0.86 | KDM4E (0.92) | KCNH2HRH3KDM4EPSMB1PSMB5 | |
| Hydrochloric Acid SCHEMBL8693860 | 0.85 | KDM4E (0.90) | KCNH2HRH3KDM4EPSMB1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208397-B2 | Small molecule antagonists of sumo related modification of CRMP2 and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208397-B2 | Small molecule antagonists of sumo related modification of CRMP2 and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200277271-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-09-03 | — | — | US | disclosed |
| US-20200277271-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-09-03 | — | — | US | disclosed |
| WO-2018144900-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144900-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2018-08-09 | — | — | WO | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-8030330-B2 | Benzothiophenes, formulations containing same, and methods | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| US-5606075-A | CYCLIZATION IN THE PRESENCE OF AN ACID CATALYST | ELI LILLY AND COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| WO-1996040678-A1 | PROCESS FOR THE SYNTHESIS OF BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040677-A1 | PROCESS FOR THE SYNTHESIS OF BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040691-A1 | VINYL SULFOXIDES AND A PROCESS FOR THEIR SYNTHESIS | ELI LILLY AND COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040676-A1 | PROCESS FOR THE SYNTHESIS OF BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5569772-A | CHEMICAL INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1996-10-29 | — | — | US | disclosed |
| US-5514826-A | INTERMEDIATES FOR 2-ARYLBENZO(B)THIOPHENES | ELI LILLY AND COMPANY (US) | 1996-05-07 | — | — | US | disclosed |
| US-5512701-A | REACTING SULFOXIDE DERIVATIVE WITH A SILYATING AGENT TO FORM SULFENATE SILYL ESTER, OPTIONALLY REACTING INTERMEDIATE WITH AN AMINE AND/OR A MERCAPTAN | ELI LILLY AND COMPANY (US) | 1996-04-30 | — | — | US | disclosed |
| WO-1996009045-A1 | ANTIESTROGENIC BENZOTHIOPHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| EP-0699673-A1 | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceutical agents | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208397-B2 | Small molecule antagonists of sumo related modification of CRMP2 and uses thereof | SUMO2, SUMO1, SUMO3 | KCNH2 760/4885HRH3 1146/4885KDM4E 732/4885 |
| US-20200277271-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | SUMO2, SUMO1, SUMO3 | KCNH2 760/4885HRH3 1146/4885KDM4E 732/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | KCNH2 1642/4885HRH3 583/4885KDM4E 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.